Prostate Cancer

Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.

Joshua Hurwitz discusses findings from a study investigating the safety of adding multifocal MRI-directed simultaneous integrated boost to stereotactic body radiation therapy in patients with prostate cancer.

Treatment with the combination of the investigational oral innate immune activator BXCL701 and pembrolizumab led to a median overall survival of 13.6 months in patients with small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer.

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Clara Hwang, MD, discusses adverse effects associated with FDA-approved agents for patients with nonmetastatic prostate cancer.

Clara Hwang, MD, discusses unmet needs in patients with nonmetastatic prostate cancer who then progress on novel agents and develop metastatic disease.

The European Medicines Agency has validated its Type II variation for enzalutamide as an option in patients with nonmetastatic hormone-sensitive prostate cancer at high risk of biochemical recurrence who are not suitable for salvage radiotherapy.

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

Clara Hwang, MD, discusses risk stratification methods used to assess the risk of metastatic disease in patients with nonmetastatic prostate cancer.

Clara Hwang, MD, highlights agents that the FDA has approved for use in patients with nonmetastatic castration-resistant prostate cancer, such as apalutamide, enzalutamide, and darolutamide.

Alexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Neeraj Agarwal, MD, discusses the benefit of PARP inhibitors compared with chemotherapy in patients with metastatic castration-resistant prostate cancer.

Zachery Roger Reichert, MD, PhD, discusses key research questions to explore in early-stage prostate cancer.

Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide.

The Japanese Ministry of Health, Labour, and Welfare has approved the combination of olaparib plus abiraterone acetate and prednisone or prednisolone for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

Zachery Roger Reichert, MD, PhD, discusses the effects novel agents and pathways have had on the treatment of patients with prostate cancer.

The FDA has accepted and granted priority review to a supplemental new drug application seeking the approval of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

Joshi Alumkal, MD, discusses the use of triplet therapy in prostate cancer.

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease following 1 prior novel hormonal therapy, meeting one of the primary end points in the primary analysis of the phase 3 CONTACT-02 trial.

Praful K. Ravi, MB, BChir, MRCP, discusses the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer, highlighting the use of the targeted radioligand lutetium Lu 177 vipivotide tetraxetan.

Zachery Roger Reichert, MD, PhD, discusses novel agents and pathways under exploration in prostate cancer.